DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Congressional Briefing on Progress in Sickle Cell Disease Treatment & Policy Implications
TUESDAY, JUNE 18, 2019 | 2:30 – 3:30 PM
DIRKSEN SENATE OFFICE BUILDING, ROOM G50
RSVP: Betsy Foss-Campbell, [email protected]
Join us for updates on Gene therapy approaches presented by prominent scientists in the field
How policymakers can support the development of treatment options for sickle cell disease
SPEAKERS
Tim Scott, United States Senator
Francesca Cook, MPH, Government Relations Committee member, ASGCT; Senior Director, Pricing and Market Access, REGENXBIO
Julie Kanter, MD, Director of Adult Sickle Cell Program; Associate Professor of Hematology and Oncology, University of Alabama at Birmingham
Punam Malik, MD, Professor of Pediatrics, Marjorie Johnson Chair of Gene and Cell Therapy, Director, Cincinnati Comprehensive Sickle Cell Center; Cancer and Blood Disease Institute, Cincinnati Children’s Hospital
Rodrick Murray, Patient advocate providing a personal story on gene therapy’s value for treating sickle cell disease
Matthew Porteus, MD, PhD, Professor of Pediatrics (Stem Cell Transplantation), Stanford University
David Williams, MD, Senior Vice President and Chief Scientific Officer, Boston Children’s Hospital; Chief, Hematology/Oncology, Boston Children’s Hospital; President, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Leland Fikes Professor of Pediatrics, Harvard Medical School
How can policymakers help support the development of gene therapies for sickle cell disease?
- Support the need for robust NIH research funding
- Support appropriations to the sickle cell disease prevention and treatment program and implementation of new surveillance and screening authorities passed in 2018
- Enable novel payment models for approved gene therapies
Hosted in partnership with the Pediatric Hospital Sickle Cell Disease Collaborative and American Society of Gene & Cell Therapy, American Society of Hematology, American Society for Transplantation and Cellular Therapy, and Sickle Cell Disease Association of America, Inc.
This event has ended.
![Congressional Briefing On Progress In Sickle Cell Disease Treatment & Policy Implications Congressional Briefing On Progress In Sickle Cell Disease Treatment & Policy Implications](https://www.onescdvoice.com/wp-content/uploads/2019/06/CapBuilDC.jpg )
![](https://www.onescdvoice.com/application/themes/onevoice-child-new/images/bookmark.png)
Related Content
-
people & placesInternational Association of Sickle Cell Nurses and Professional AssociatesThe International Association of Sickle ...
-
Community CenterDarryl Watkins Stays Positive in Spite of Sickle Cell DiseaseDarryl Watkins has the HbSS variant of s...
-
education & researchImproving Quality of Care for Sickle Cell Patients in the Pediatric Emergency DepartmentOBJECTIVE: The aim of this study was to ...
-
education & researchGuidelines on Red Cell Transfusion in Sickle Cell Disease. Part I: Principles and Laboratory AspectsBlood transfusion in the management of s...
-
news & eventsSickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
-
news & eventsYoga for Chronic Pain – US Pain FoundationDuring this interactive live webinar, in...
-
news & eventsStudy challenges view that sickle cell trait increases mortality riskSurprising findings from a study of heal...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
![](https://www.onescdvoice.com/application/themes/onevoice-child-new/images/scdalogo.png)
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.